2014


To access this material please log in or register

Register Authorize
2014/№5

Acetylsalicylic acid in primary prevention of cardiovascular diseases

Seliverstova D. V., Evsina O. V.

Keywords: acetylsalicylic acid, treatment, preventive measures, cardiovascular diseases


DOI: 10.18087/rhj.2014.5.1987

The review provides information about study results and recommendations on aspirin treatment for primary prevention of CVD.
  1. Fuster V, Fallon JT, Badimon JJ, Nemerson Y. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention. Thrombosis and Hemostasis. 1997 Jul; 78 (1):247–55.
  2. Демографический ежегодник России 2013 Статистический сборник. Федеральная служба государственной статистики. – М.: «Росстат», 2013. – 543с.
  3. Роль аспирина в сердечно-сосудистой профилактике (исследования 2004 г.) Клиническая фармакология и терапия. 2005;14 (3):1–4.
  4. Остроумова О. Д. Ацетилсалициловая кислота – препарат номер один для лечения сердечно-сосудистых заболеваний: основные показания к применению, клинические преимущества, эффективные дозы и пути повышения переносимости. Русский медицинский журнал. 2003;11 (5):275–81.
  5. Graham I, Atar D, Borch-Johansen K et al. Европейские рекомендации по профилактике сердечно-сосудистых заболеваний в клинической практике. Пер. с англ. Рац. фармакотер. в кардиол. 2008;4:111–22.
  6. Smith WL. Molecular mechanisms of aspirin action. Drug News and Perspect. 1991;4 (6):362–66.
  7. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity interred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol. 1995;2 (8): 637–43.
  8. Upchurch RG, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic consequences of oxidation of fibrinogen and their inhibition by aspirin. J Thrombosis and Thrombolysis 1998;5 (1):9–14.
  9. Williams S, Fatah K, Hjemdahl P, Blombak M. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J. 1998 Nov; 19 (11):1666–72.
  10. Jorneskog G, Fatah K, Blomback M. Fibrin gel structure in diabe­tic patients before and during treatment with acetyl salicylic acid: a pilot study. Fibrinolysis & Proteolysis. 1998;12 (6):360–65.
  11. Wallen NH, Ladjevardi M. Influence of low-and high-dose aspirin treatment on thrombin generation in whole blood. Thrombosis Res. 1998 Nov 15;92 (4):189–94.
  12. Botting RM et al. The anti-thrombotic and fibrinolytic actions of aspirin. In: JR Vane, RM Botting (Hrsg.): Aspirin and other salicy­lates. – Chapman & Hall London New York-Tokyo-Melbourne-Madras, 1992. – р. 245–91.
  13. Basinski A, Naylor CD. Aspirin and fibrinolysis in acute myocardial infarction: meta-analytic evidence for surgery. J Clin Epidemiol. 1991;44 (10):1085–96.
  14. Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol. 1992;19 (3):671–77.
  15. Amin AR, Attur MG, Pillinger M, Abramson SB. The pleiotropic functions of aspirin: mechanisms of action. Cell Mol Life Sci. 1999 Oct 15;56 (3-4):305–12.
  16. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IkappaB kinase-beta. Nature. 1998 Nov 5;396 (6706):77–80.
  17. Cleland JGF. Aspirin. In: Mann DL, ed Heart Failure:A Companion to Braunwold’s Hear Disease. New York: Elsevier Science, – 2004. – p. 660–669.
  18. Grosser N, Schőder H. Aspirin protecs endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Thromb Vask Biol. 2003 Aug 1;23 (8):1345–51.
  19. Geppert A, Graf S, Beckmann R et al. Concentration of endogenous tPA antigen in coronary artery disease. Relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arterioscler Thromb Vasc Biol. 1998;18 (10):1634–42.
  20. Levin RI, Harpel PC, Weil D et al. Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity. J Clin Invest. 1984 Aug;74 (2):571–80.
  21. Oberle S, Polte T, Abate A et al. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res. 1998 May 18;82 (9):1016–20.
  22. Roncaglioni MC, Ulrich MM, Muller AD et al. The vitamin K-antagonism of salycilate and warfarin. Thromb Res. 1986 Jun 15;42 (6):727–36.
  23. Baigent C, Blackwell L, Collins R et al; Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analisis of individual participant data from randomized trials. Lancet. 2009 May 30;373 (9678):1849–60.
  24. Ridker PM, Cook NR, Lee IM et al. A randomized trial of Low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005 Mar 31;352 (13):1293–304.
  25. Saito Y, Morimoto T, Ogawa H et al. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes Care. 2011 Feb;34 (2):280–5.
  26. Эффективность и безопасность лекарственной терапии при первичной и вторичной профилактике сердечно-сосудистых заболеваний. Национальные рекомендации ВНОК. Рациональная фармакотерапия в кардиологии 2011; (Приложение 5):24–31.
  27. Sanmuganathan PS, Ghahramani P, Jackson PR et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart. 2001;85 (3):265–71.
  28. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007 Sep;14 (Suppl 2):S1‑S113.
  29. Calonge N, Petitti DB, DeWitt TG et al. Aspirin for the Prevention of Cardiovascular Disease: U. S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2009 Mar 17;150 (6):396–404.
  30. Bhatt DL, Scheiman J, Abraham NS et al. ACCF / ACG / AHA 2008 expert consensus document on reducing the gastrointestinal risk of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Circulation. 2008 Oct 28;118 (18):1894–909.
  31. Kubler W, Darius H. Primary prevention of coronary heart disease with aspirin. Z Kardiol. 2005;94 (Suppl 3):66–73.
Seliverstova D. V., Evsina O. V. Acetylsalicylic acid in primary prevention of cardiovascular diseases. Russian Heart Journal. 2014;79 (5):298–302

To access this material please log in or register

Register Authorize
Ru En